Building the Future of Measurable Nutrition

Title

23 Investor Slots

$750,000

Private friends & family round - limited access

Book a call to dig deeper

FAQs

Need more details on the investment?

Additional Information

How will the money raise be spent?

Inventory & Production ($250k): Funding the first commercial run of OMG8+ and OMAMA+ bars and raw material buffers for 6,000+ units.

 

Marketing & Acquisition ($200k): Executing the viral "Contagious Waitlist" campaign and engaging a top-tier crowdfunding management agency.

 

Tech Stack: BioTrack App ($150k): Development of the MVP app for HIPAA-compliant result tracking and leaderboard gamification.

 

Operating Buffer ($150k): 6 months of G&A, DC rent, and working capital to reach the Series A trigger.

 

Our current recurring burn rate is $17,000 per month — nominal for a company at this stage of clinical validation and market readiness. This lean profile reflects a founding team that performs $1.16M+ in annual functional value (legal, creative, strategy, CPG exit expertise) at near-zero cash cost. Every dollar of bridge capital goes to product, proof, and customer acquisition — not executive overhead.

Why are you confident omega reboot can achieve hockey stick growth?

We combine proven results + testing + subscription, which creates powerful retention and recurring revenue.

Customers see their Omega-3 Index rise to 8% (clinically validated target) and drop if they stop → strong stickiness.

Our clinical trials show users reach 8% in ~30 days and significantly reduce inflammation (CRP).

Competitors don’t measure outcomes—we do

With clinicians, influencers, and a scalable subscription model, we convert trust into rapid, compounding growth.

How large is the market and what share can you capture?

We operate across Omega-3, functional nutrition, and longevity; a multi-billion dollar global market.

Even competitors with non-effective products have scaled to ~400,000 monthly subscribers, despite high churn.

 

This shows:

Massive demand already exists.

The category is proven.

A product that actually works + proves it, can capture significant share.

how does the subscription model drive growth and retention?

We start with a focused launch of ~1,000 customers on a 60-day program, guaranteed to reach 8%.

 

Strategy:

Seed product with clinicians, influencers, and practitioners.

Generate visible results + social proof + test data.

Drive pre-orders and subscriptions from proven outcomes.

In the current market, competitors replace ~40,000 users monthly due to churn.

 

We win by:

Reducing churn (product works + measurable results).

Increasing LTV through subscription + progress tracking.

Scaling acquisition through trusted voices and clinical validation.

Funding enables this initial push—after which cash flow becomes self-reinforcing.

How soon do you expect to lauch?

We are ready to launch in May.

 

Infrastructure, distribution, and GTM are in place.

Funding unlocks our first full production run.

 

Pipeline includes:

New flavors (Peanut Butter, Raspberry Vanilla)

OMAMA prenatal bar (targeted Omega-3 +multivitamin for pregnancy)

FAQs

How will the money raise be spent?

Inventory & Production ($250k): Funding the first commercial run of OMG8+ and OMAMA+ bars and raw material buffers for 6,000+ units.

 

Marketing & Acquisition ($200k): Executing the viral "Contagious Waitlist" campaign and engaging a top-tier crowdfunding management agency.

 

Tech Stack: BioTrack App ($150k): Development of the MVP app for HIPAA-compliant result tracking and leaderboard gamification.

 

Operating Buffer ($150k): 6 months of G&A, DC rent, and working capital to reach the Series A trigger.

 

Our current recurring burn rate is $17,000 per month — nominal for a company at this stage of clinical validation and market readiness. This lean profile reflects a founding team that performs $1.16M+ in annual functional value (legal, creative, strategy, CPG exit expertise) at near-zero cash cost. Every dollar of bridge capital goes to product, proof, and customer acquisition — not executive overhead.

Why are you confident omega reboot can achieve hockey stick growth?

We combine proven results + testing + subscription, which creates powerful retention and recurring revenue.

Customers see their Omega-3 Index rise to 8% (clinically validated target) and drop if they stop → strong stickiness.

Our clinical trials show users reach 8% in ~30 days and significantly reduce inflammation (CRP).

Competitors don’t measure outcomes—we do

With clinicians, influencers, and a scalable subscription model, we convert trust into rapid, compounding growth.

How large is the market and what share can you capture?

We operate across Omega-3, functional nutrition, and longevity; a multi-billion dollar global market.

Even competitors with non-effective products have scaled to ~400,000 monthly subscribers, despite high churn.

 

This shows:

Massive demand already exists.

The category is proven.

A product that actually works + proves it, can capture significant share.

how does the subscription model drive growth and retention?

We start with a focused launch of ~1,000 customers on a 60-day program, guaranteed to reach 8%.

 

Strategy:

Seed product with clinicians, influencers, and practitioners.

Generate visible results + social proof + test data.

Drive pre-orders and subscriptions from proven outcomes.

In the current market, competitors replace ~40,000 users monthly due to churn.

 

We win by:

Reducing churn (product works + measurable results).

Increasing LTV through subscription + progress tracking.

Scaling acquisition through trusted voices and clinical validation.

Funding enables this initial push—after which cash flow becomes self-reinforcing.

How soon do you expect to lauch?

We are ready to launch in May.

 

Infrastructure, distribution, and GTM are in place.

Funding unlocks our first full production run.

 

Pipeline includes:

New flavors (Peanut Butter, Raspberry Vanilla)

OMAMA prenatal bar (targeted Omega-3 +multivitamin for pregnancy)

How will the money raise be spent?

Inventory & Production ($250k): Funding the first commercial run of OMG8+ and OMAMA+ bars and raw material buffers for 6,000+ units.

 

Marketing & Acquisition ($200k): Executing the viral "Contagious Waitlist" campaign and engaging a top-tier crowdfunding management agency.

 

Tech Stack: BioTrack App ($150k): Development of the MVP app for HIPAA-compliant result tracking and leaderboard gamification.

 

Operating Buffer ($150k): 6 months of G&A, DC rent, and working capital to reach the Series A trigger.

 

Our current recurring burn rate is $17,000 per month — nominal for a company at this stage of clinical validation and market readiness. This lean profile reflects a founding team that performs $1.16M+ in annual functional value (legal, creative, strategy, CPG exit expertise) at near-zero cash cost. Every dollar of bridge capital goes to product, proof, and customer acquisition — not executive overhead.

Why are you confident omega reboot can achieve hockey stick growth?

We combine proven results + testing + subscription, which creates powerful retention and recurring revenue.

Customers see their Omega-3 Index rise to 8% (clinically validated target) and drop if they stop → strong stickiness.

Our clinical trials show users reach 8% in ~30 days and significantly reduce inflammation (CRP).

Competitors don’t measure outcomes—we do

With clinicians, influencers, and a scalable subscription model, we convert trust into rapid, compounding growth.

How large is the market and what share can you capture?

We operate across Omega-3, functional nutrition, and longevity; a multi-billion dollar global market.

Even competitors with non-effective products have scaled to ~400,000 monthly subscribers, despite high churn.

 

This shows:

Massive demand already exists.

The category is proven.

A product that actually works + proves it, can capture significant share.

how does the subscription model drive growth and retention?

We start with a focused launch of ~1,000 customers on a 60-day program, guaranteed to reach 8%.

 

Strategy:

Seed product with clinicians, influencers, and practitioners.

Generate visible results + social proof + test data.

Drive pre-orders and subscriptions from proven outcomes.

In the current market, competitors replace ~40,000 users monthly due to churn.

 

We win by:

Reducing churn (product works + measurable results).

Increasing LTV through subscription + progress tracking.

Scaling acquisition through trusted voices and clinical validation.

Funding enables this initial push—after which cash flow becomes self-reinforcing.

How soon do you expect to lauch?

We are ready to launch in May.

 

Infrastructure, distribution, and GTM are in place.

Funding unlocks our first full production run.

 

Pipeline includes:

New flavors (Peanut Butter, Raspberry Vanilla)

OMAMA prenatal bar (targeted Omega-3 +multivitamin for pregnancy)

Need more details on the investment?

Additional Information